To be continued today … Sanofi – 07/31/2025 at 08:02

(AOF) – Sanofi has unveiled results in clear improvement. Meanwhile, In the second quarter, the French laboratory generated a turnover of 9.994 billion euros, up 6 %. Additionally, Meanwhile, At the same time, the free cash flow jumped 65.8 %, to 1.429 billion euros. Similarly, Finally, the net profit of activities fell slightly 0.6 %, to 1.940 billion euros. Meanwhile, Over the entire first half, income increased by 8.3 %to 19.889 billion euros, the free cash flow flambé by 474.3 %, to 2.458 billion euros and the net profit of activities increased by 7.6 %, to 4.152 billion euros.

Over the period from April to June, group sales were brought by new pharmaceutical launches (+39.8 %), sales of Dupixent (+21.1 %) and vaccines (+10.3 %).

In terms of prospects. Sanofi has raised its objective of annual continued today … sanofi – turnover which should now experience growth as a percentage at a high figure at constant exchange rates, against an average increase in high figure. The net profit per share is always expected in strong rebound (+9.7 % in the first half) in the low range of a two -digit percentage (excluding share buyout).

AOF – Find out more

Key points

– 5th global and European pharmaceutical group, created in 1994;

– Sales of € 41.1 billion from 7 divisions: immunology for 33 %. rare diseases for 14 %, neurology for 1 %, oncology for 2 %, vaccines for 4 %and other medi-care (Lantus, Toujejo, Lovenox, Plavix, Thymoglobulin, Praluent …) for 46 %.

– increasing share of the United States (45 %) and the rest of the world (27 %) ahead of Europe (18 %);

continued today … sanofi – – Ambition: positioning of a biopharmaceutical -based on science, focused on innovative drugs & vaccines, now its place of world n ° 1 in vaccines and targeting that of world n ° 1 in immunology;

– Capital exploded (excluding L’Oréal -9.4 % of shares with 16.95 % of voting rights – and employees -2.6 %), Frédéric Oudéa presiding the council of 17 administrators, Paul Hudson being CEO.

Challenges

– Agility of the business model:

– Capital allocation in 4 shares: organic growth. external growth, continuous increase, for 30 years, of the dividend then acquisition of action,

– Productivity via R&D and, in factories, via digital (€ 2 billion in savings),

– Restructuring of the portfolio:

-Inrichment in organic products,

– 1/3 reduction of product families in 2025, vs 2020, via the transfers continued today … sanofi – of + 50 % of the capital of Opella, world n ° 3 of prescription drugs, and Aspégic, Kardégic, Kardégic,

– Research focused on 5 areas: immunology & inflammation with the objective of becoming world n ° 1, oncology, neurology (sclerosis …. rare hematological diseases & rare diseases then vaccines, with nearly 100 projects in progress,

– innovation :

– Developed in collaboration: Regeneron, Kymera, Teva, Skbioscience…,

– Accelerated by acquisitions —Kiadis, Biopharma, Kymab, Whitelab Genomics – and partnerships -Aventyx, Radiomedix, Meiragtx…,

– Supported by platforms: small molecules, anti-corps, hemogenetic proteins, artificial genomy…;

– Planet Mobilization environmental strategy aimed at carbon neutrality in 2030:

– 2030: 100 % sustainable electricity consumption against 50 % in 2021,

– 2027: elimination of plastic packaging for vaccines,

– 2025: eco -design of all new products; continued today … sanofi –

– credit lines indexed to sustainable development;

– Success of the 9 launches 2024 bringing 11 % of sales (Altuviiio, Beyfortus, Cablivi, etc.);

– healthy assessment with free self -financing of € 6 billion and a net debt of € 8.8 billion.

Challenge

– Continuation of the reduction of dependence on the duxipent (29 of sales). sensitivity of the result to exchange variations;

– follow -up of the 5 “priority” drugs: Beyfortus, amcenestrant (breast cancer) upstairs, Fitusiran and Efanesoctocog (hemophilia) then tolebrutinib (multiple sclerosis);

– Force you pipeline:

– In 2024, 5 positive results in phase 3: Fitusiran, Dupixent, Rilzabrutinib, Tolebrutinib and Sarclisa and next phase 3 launches for Duvakitug and SPO202,

– 2025: 6 phase results 3 and 7 expectations of regulatory authorization,

– After the sale continued today … sanofi – of + 50 % of Opella’s capital, world n ° 3 of prescription drugs, vitamins and food or mineral supplements;

– after performance higher than forecasts, 2025 objectives: increase in income close to & 0 % and strong rebound in action per share, in the database of the range 10 % -20 %;

– Dividend 2024 rising € 3.92 and 5 billion € program for share buyback.